MMP9 was shown to be activated in numerous cancers and to contribute to tumor angiogenesis by increasing the bioavailability of VEGF, basic fibroblast growth factor (bFGF) by degrading collagen types IV, XVIII and perlecan [21, 22]. This evidence concerns the gene VEGFA and cancer.